Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285462 | 0.94 | HDAC1 (0.65) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL6290249 | 0.92 | HDAC8 (0.50) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL6287690 | 0.88 | HDAC1 (0.61) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL6290426 | 0.85 | HDAC1 (0.54) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL6286718 | 0.84 | HDAC1 (0.50) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| Trifluoroacetic Acid SCHEMBL6290995 | 0.84 | HDAC1 (0.54) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL6287588 | 0.84 | HDAC1 (0.63) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL7034718 | 0.83 | HDAC1 (0.63) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| Trifluoroacetic Acid SCHEMBL6290396 | 0.83 | HDAC1 (0.55) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL7040125 | 0.82 | HDAC1 (0.58) | HDAC1HDAC8HDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | HDAC1 3488/4885HDAC8 4710/4885HDAC3 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.